This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Aging/ Geriatrics  • Ophthalmology  • Ophthalmological Disorders  • Macular Degeneration  • Alert me on articles by topic  Social Bookmarking   What's this?

Commentary by Barbara E. K. Klein, MD, MPH,; Ronald Klein, MD, MPH

JAMA. 2009;301(20):2152-2153.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

ARCHIVES OF OPHTHALMOLOGY

Forecasting Age-Related Macular Degeneration Through the Year 2050: The Potential Impact of New Treatments

David B. Rein, PhD; John S. Wittenborn, BS; Xinzhi Zhang, MD, PhD; Amanda A. Honeycutt, PhD; Sarah B. Lesesne, BS; Jinan Saaddine, MD, MPH; for the Vision Health Cost-Effectiveness Study Group

Objective: To forecast age-related macular degeneration (AMD) and its consequences in the United States through the year 2050 with different treatment scenarios.

Methods: We simulated cases of early AMD, choroidal neovascularization (CNV), geographic atrophy (GA), and AMD-attributable visual impairment and blindness with 5 universal treatment scenarios: (1) no treatment; (2) focal laser and photodynamic therapy (PDT) for CNV; (3) vitamin prophylaxis at early-AMD incidence with focal laser/PDT for CNV; (4) no vitamin prophylaxis followed by focal laser treatment for extra and juxtafoveal CNV and anti–vascular endothelial growth factor treatment; and . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?